A
ACRV
Acrivon Therapeutics, Inc. Common Stock
$1.72
Current Price
1W
1M
3M
6M
1Y
All
AI analysis
Read what the AI thinks of Acrivon Therapeutics, Inc. Common Stock in the app.
Analyses are generated by AI from public data and are not investment advice.
Get the app
Key figures
Dividend per share
—
Yield
—
EPS
-$1.88
P/E
—
Data as of Oct 1
Why it matters for the long term
Over 10-20 years, what drives a share up is the growth of its profits (EPS) + reinvested dividends. The P/E tells you whether you are paying a lot or a little for that growth. In short: rising EPS + reasonable P/E + growing dividend = good long-term candidate.
Upcoming events
Quarterly earnings
Expected EPS: -$0.45
Nov 12
Posts
No posts about ACRV yet.
About Acrivon Therapeutics, Inc. Common Stock
Acrivon Therapeutics is a small clinical-stage biotech company working on cancer drugs. It uses a screening platform to match each drug to the patients whose tumors are most likely to respond. The company has no products on the market and no sales, so it pays for its research by raising money from investors.